Roche may have to up Illumina bid as it extends tender offer
This article was originally published in Scrip
Roche's hostile takeover attempt of gene sequencing firm Illumina has had a lukewarm response from Illumina's shareholders, forcing Roche to extend its tender offer period. Illumina shareholders now have until 23 March to tender their shares at the unrevised; the offer was previously set to expire on 24 February.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.